ER+/HER2 − breast cancer is commonly treated with endocrine therapy combined with CDK4/6 inhibitors (CDK4/6i), including palbociclib, ribociclib, and abemaciclib. Although these combinations have improved clinical outcome, resistance remains frequent, highlighting the need to identify vulnerabilities that enhance CDK4/6i response. To uncover metabolic dependencies associated with CDK4/6i sensitivity, we performed an unbiased loss-of-function screen targeting ∼2,800 metabolic genes. This identified lipase H (LIPH), a phosphatidic acid-selective phospholipase A1 that generates lysophosphatidic acid (LPA), as a candidate vulnerability in palbociclib-treated ER+/HER2- breast cancer cells. LIPH depletion reduced LPA levels and sensitized multiple ER+ models to palbociclib, ribociclib, and abemaciclib. Mechanistically, LIPH-derived LPA activated LPAR2-dependent AMPK/p38 signaling, sustaining CD36 expression. CD36 regulated cyclin D1 levels and cell-cycle progression, while LIPH or CD36 depletion reduced cyclin D1, induced G0/G1 accumulation, and enhanced CDK4/6i sensitivity. Conversely, exogenous LPA restored CD36 and cyclin D1 expression in LIPH-silenced cells. Genetic or pharmacological CD36 targeting potentiated CDK4/6i efficacy in endocrine-sensitive and therapy-resistant ER+ models, as well as in patient-derived organoids. Clinically, high LIPH/CD36 scores were associated with poor response to CDK4/6i-based therapy, while elevated LIPH, CD36, or combined LIPH/LPAR2/CD36 expression correlated with worse outcome in ER+/HER2 − breast cancer cohorts. Together, our findings identify the LIPH–LPA–LPAR2–CD36–cyclin D1 axis as a lipid-signaling vulnerability that modulates CDK4/6i response and propose LIPH and CD36 as candidate therapeutic targets and biomarkers in ER+/HER2- breast cancer.